Navigation Links
Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update
Date:5/6/2008

- Conference Call Today at 5:00 p.m. Eastern Time -

SOUTH SAN FRANCISCO, Calif., May 6 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today reported on its corporate progress and financial results for the first quarter ended March 31, 2008.

"During the first quarter, we made significant progress in moving our clinical trials forward and generating data to demonstrate the potential of picoplatin as a new generation platinum therapy," said Jerry McMahon, Ph.D., chairman and CEO of Poniard. "Our pivotal Phase 3 SPEAR trial in small cell lung cancer continues to enroll patients. Today, we are pleased to announce the completion of patient enrollment in our Phase 2 trial in metastatic colorectal cancer. The results of our Phase 1 trials in prostate cancer and colorectal cancer were presented earlier this year. Encouraging bioavailability data has been presented from our ongoing Phase 1 trial of oral picoplatin. We secured commercial manufacture and supply of picoplatin drug substance. A new chief medical officer was appointed to expedite the clinical development of picoplatin through product approval. Our accomplishments this quarter are consistent with the development of picoplatin as a platform product addressing multiple indications, combinations and formulations."

First Quarter and Recent Highlights

Picoplatin and Development Pipeline

* Small Cell Lung Cancer: Presented final data from our Phase 2 trial

of picoplatin in small cell lung cancer (SCLC) at the International

Association for the Study of Lung Cancer and the European Society

for Medical Oncology's 1st European Lung Canc
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Poniard Pharmaceuticals Announces Upcoming Conference Participation
2. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
3. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Announces Upgrade of Stock Listing to NASDAQ Global Market
5. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
6. Onyx Pharmaceuticals Reports 2008 First Quarter Results
7. SGX Pharmaceuticals Schedules Teleconference and Webcast to Discuss First Quarter 2008 Results and Provide Pipeline Update
8. Israels Prestigious Presidents Conference to Feature Oramed Pharmaceuticals Revolutionary Oral Insulin Capsule
9. Michael D. Taylor, Ph.D., Joins Cequent Pharmaceuticals Board of Directors
10. Keryx Biopharmaceuticals to Present at the Deutsche Bank 33rd Annual Health Care Conference
11. GlaxoSmithKline Commences Tender Offer to Acquire Sirtris Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Canada (PRWEB) July 10, 2014 ... present in very low abundance and are often ... challenging and time-consuming. , Join presenters Dr. Rowel ... and Dr. John Anders, Head of Quality at ... spectrometer-based approach that can speed detection and quantitation ...
(Date:7/10/2014)... 10, 2014 Understanding the need for ... lines, and the gap that currently exists in this ... its industry-leading portfolio of validated ion channel and GPCR ... cell lines, as ion channels control many critical physiological ... activity creates the potential to treat a variety of ...
(Date:7/10/2014)... 2014 Unraveling life’s mysteries can intrigue, ... Archer Family purchased a DNA test to ... up with a lifetime of memories, sharing, and closeness. ... members’ DNA genuinely brought the family closer together. ... into genetic history and prior to taking the ...
(Date:7/10/2014)... July 10, 2014 OMICS Group’s 5th ... during 18-20 August, 2014 at Double Tree by Hilton ... recent developments in Analytical & Bioanalytical research methods only ... Speaking on this occasion, Dr. Srinubabu Gedela, MD of ... conference is a remarkable one in bringing a unique ...
Breaking Biology Technology:Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4
... , BOTHELL, Wash., Aug. 7 SCOLR Pharma, ... for the three and six months ended June 30, 2009. ... President and CEO, said, "We continue to advance discussions with a ... potential partners have been committing resources to due diligence and preliminary ...
... HUNTSVILLE, Ala., Aug. 7 EGEN, Inc. (EGEN), a biopharmaceutical ... that Jason Fewell, Ph.D., has been promoted from Director of ... , , Dr. Fewell possesses more than ... industry and has served at EGEN since 2003 as Director ...
... BRISBANE, Calif., Aug. 7 InterMune, Inc. (Nasdaq: ... Officer and President of InterMune, will present at the Canaccord Adams ... at 10:30 a.m. EDT. , , To access ... parties may log on to the investor relations page of InterMune,s ...
Cached Biology Technology:SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 2SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 3SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 4SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 5SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 6SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 7SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 8EGEN, Inc. Announces the Promotion of Jason Fewell, Ph.D., to Vice-President of Preclinical Research and Development 2
(Date:7/11/2014)... risk of kidney injury related to the use of ... of HES molecules, according to a report in ... Anesthesia Research Society (IARS). , The "total mass of ... cultured human renal proximal tubule cells (PTCs), concludes the ... University Hospital Wrzburg, Austria. Other factorssuch as differences ...
(Date:7/11/2014)... the hippocampus, the marginal division of the striatum ... is the impact degree of substance P in ... function? Yan Yu and his team, College of ... immunofluorescence staining, that substance P receptor, neurokinin 1 ... marginal division of normal rats. Unilateral or bilateral ...
(Date:7/11/2014)... receptor type 1 can inhibit voltage-gated calcium ... neurotransmitter release. However, some scholars demonstrated that ... Ca2+ influx and increase neurotransmitter release. Dr. ... Affiliated to Tongji Medical College, Huazhong University ... cell voltage-clamp and calcium imaging in cultured ...
Breaking Biology News(10 mins):In lab studies, hydroxyethyl starch has direct harmful effects on kidney cells 2
... Ohio Researchers, health care engineers and medical ... National Conference on Value-driven Engineering to Improve Medical ... Austen BioInnovation Institute in Akron (ABIA) and sponsored ... some of the nation,s leading biomedical device engineering ...
... many aspects of who we are from the colour ... but how are the genes, and consequently the proteins they ... new group of molecules which control some of the fundamental ... developing new therapies for treating neurodegenerative diseases. The research, ...
... in German . Leipzig/Dresden/Freiburg. In recent ... around the world. As a team of researchers from the ... Dresden and the University of Freiburg headed by the UFZ ... global pollination benefit" in the open-access journal PLoS ONE ...
Cached Biology News:Medical device, health professionals attend first national conference on value-driven engineering 2Medical device, health professionals attend first national conference on value-driven engineering 3Doubling the information from the double helix 2Global prices of pollination-dependent products such as coffee could rise in the long term 2Global prices of pollination-dependent products such as coffee could rise in the long term 3
5 minutes from gel band to purified DNA...
BD IMag Anti-Mouse CD90.2 (Thy1.2) Particles-MSC 2 x 109 cells...
... Agarose overlays are commonly ... Many commercial "DNA grade" agaroses ... toxic to insect cells or ... to obtain good overlays. Novagen's ...
AgarPlaque Plus Agarose 50 grams...
Biology Products: